 |
| AstraZeneca is the UK's largest pharmaceutical company. (Source: The Guardian) |
The move is the latest in a series of deals to expand AstraZeneca's product portfolio, along with positive results from a late-stage rare disease drug.
| Related News |
 AstraZeneca will accompany Vietnam in achieving its goals. |
EsoBiotec, a private company founded four years ago in Mont-Saint-Guibert, is developing in-vivo cell therapies that help the immune system attack cancer cells. The technology could shorten treatment times from weeks to just minutes, opening up wider access for patients.
The deal is the latest move by AstraZeneca – Britain’s biggest pharmaceutical group with a market capitalisation of £186bn – to expand its global operations. EsoBiotec’s technology uses targeted lentiviruses to deliver genetic instructions to immune cells such as T-cells, helping them recognise and kill cancer cells.
In addition, this technology also has potential applications in the treatment of autoimmune diseases. With this method, cell therapy can be performed simply through direct injection, instead of the complicated process of traditional therapies - which require taking cells from the patient, editing genes outside the body and infusing them back after many weeks.
“We believe this technology could revolutionize cell therapy, expanding access to treatment for more patients around the world,” said Susan Galbraith, executive vice president of cancer research and development at AstraZeneca.
EsoBiotec recently began clinical trials for multiple myeloma, a form of bone marrow cancer. Under the deal, AstraZeneca will pay an initial $425 million to acquire the Belgian company, with up to $575 million in additional payments depending on the drug’s development and approval. AstraZeneca has previously made several targeted acquisitions, including China’s Gracell Biotechnologies, a company specializing in CAR-T cancer therapies.
In another development, on the same day, AstraZeneca announced that the European Union (EU) has approved the drug Imfinzi, becoming the first and only immunotherapy approved to treat limited-stage small cell lung cancer in patients who have not progressed after platinum-based chemoradiation therapy.
Source: https://baoquocte.vn/astrazeneca-chi-1-ty-usd-thau-tom-cong-ty-cong-nghe-bi-hoc-tiem-nang-trong-lieu-phap-te-bao-307912.html
Comment (0)